Long-Term Clinical Outcomes Following Treatment of Actinic Keratosis with Imiquimod 5% Cream

Lee, Peter K.; Harwell, William B.; Loven, Keith; Phillips, Tania J.; Whiting, David; Andres, Kara L.; Lee, James H.

doi:10.1097/00042728-200506000-00008

Cited by 34 publications

(22 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been suggested that this may explain the sustained lesion clearance that has been observed after treatment with imiquimod 5%. 20,21 In the current studies, the peak increase in lesion counts (cycle 1) was noted to be greater in the imiquimod 3.75% group than in the 2.5% group. Although this might be a result of an imbalance in baseline severity of subclinical disease, it may also be that greater immune activation results in unmasking of smaller foci of abnormal cells.…”

Section: Discussionsupporting

confidence: 47%

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles

Hanke

Beer

Stockfleth

et al. 2010

Journal of the American Academy of Dermatology

138

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 47%

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles

Hanke

Beer

Stockfleth

et al. 2010

Journal of the American Academy of Dermatology

138

View full text Add to dashboard Cite

“…14 The corresponding data for initial complete clearance were 42.2% for ingenol mebutate and 3.7% for vehicle (vehicle-adjusted complete clearance rate of 38.5%), 8 which is similar to that for imiquimod (vehicle-adjusted complete clearance rate of 39.1%). Sustained clearance 12 months after initial clearance using a 16-week schedule of imiquimod was comparable to that of the 12-week (4 ϩ 4 ϩ 4) regimen, 15 whereas the sustained clearance with imiquimod, 3.75%, was in the range of 41% to 48% in the subgroup of patients initially cleared. 4 Early trials demonstrated that actinic keratoses of the trunk or extremities are more difficult to treat than those on the face or scalp.…”

Section: Commentmentioning

confidence: 76%

Long-term Follow-up Study of Ingenol Mebutate Gel for the Treatment of Actinic Keratoses

Lebwohl¹,

Shumack²,

Gold³

et al. 2013

JAMA Dermatol

118

View full text Add to dashboard Cite

Importance: Ingenol mebutate is the active agent (a macrocyclic diterpene ester) in the sap of the plant Euphorbia peplus. This herb has been used as a traditional remedy for several different skin lesions, including skin cancers.Objective: To assess 12-month recurrence rates and safety associated with ingenol mebutate gel treatment in patients who previously had achieved complete clearance of actinic keratoses. Design and Setting:The treatment area was observed for recurrence for 12 months after the original study. Patients were treated in an outpatient setting.Participants: Patients received ingenol mebutate gel, 0.015%, daily for 3 consecutive days for actinic keratoses on the face or scalp or ingenol mebutate gel, 0.05%, daily for 2 consecutive days for actinic keratoses on the trunk or extremities. Study participants had achieved complete clearance in a prespecified 25-cm 2 area at day 57 of their original trial. Main Outcome Measures:Recurrence rates and safety were assessed.Results: In total, 108 patients with complete clearance of face or scalp lesions in the original trial and 76 patients with complete clearance of trunk or extremity lesions in the original trial were enrolled in the 12-month observational follow-up study. Of these, 100 patients (face or scalp) and 71 patients (trunk or extremities) completed all 12 months. The sustained lesion reduction rates compared with baseline were 87.2% for the face or scalp and 86.8% for the trunk or extremities. The estimated median times to recurrence were 365 days (face or scalp) and 274 days (trunk or extremities). There were no safety concerns during the follow-up period. Conclusion and Relevance:Ingenol mebutate gel applied as field therapy for 2 or 3 consecutive days to treat actinic keratoses produced clinically relevant sustained clearance and long-term lesion reduction.

show abstract

“…When considering which of the wide spectrum of treatment methods available for AK to use, factors such as efficacy, tolerability, convenience, cosmetic outcome and cost must be taken into account. Many studies have indicated the efficacy of topical DFS and IMQ in the treatment of AK 4–16 . The efficacy results of various clinical studies using DFS and IMQ to treat AK are shown in Table 4.…”

Section: Discussionmentioning

confidence: 99%

Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses

Akarsu

Aktan

Atahan

et al. 2011

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

show abstract

Long-Term Clinical Outcomes Following Treatment of Actinic Keratosis with Imiquimod 5% Cream

Cited by 34 publications

References 3 publications

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles

Long-term Follow-up Study of Ingenol Mebutate Gel for the Treatment of Actinic Keratoses

Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses

Contact Info

Product

Resources

About